Dentsply Sirona Inc (XRAY)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Dentsply Sirona Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 13.40 $ — 75% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -2.1% failed
- More than 10% revenue growth is expected for the coming year 2.1% failed
- Share count grows by less than 3% a year -2.6% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -0.2% failed
- Gross margin at 40% or higher and without meaningful erosion 50.0% failed
- Goodwill from acquisitions does not grow faster than revenue 21.2% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 2,713 m passed
- Return on capital at 15% or higher, or up versus two years ago 6.2% passed
- Insiders hold at least 10% or are net buyers 0.6% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 0.3% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 17
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.42 | 1.40 – 1.45 | 3,584 | -11.3% | 18 |
| 12/31/2027 | 1.55 | 1.46 – 1.67 | 3,658 | 9.2% | 18 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.36 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -2.12 | -766.10 | 905 | -10.60 | -47.50 | 87 | 36 |
| 2025: Q1 | 0.10 | 15.90 | 879 | -7.80 | 2.30 | 7 | -12 |
| 2025: Q2 | -0.23 | – | 936 | -4.90 | -4.80 | 48 | 16 |
| 2025: Q3 | -2.14 | – | 904 | -4.90 | -47.20 | 79 | 40 |
| 2025: Q4 | -0.73 | – | 961 | 6.20 | -15.20 | 101 | 60 |
| 2026: Q1 | -0.05 | -150.00 | 880 | 0.10 | -1.10 | 40 | -12 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 3,745 | 455 | 430 | 1.94 | 563 | 8,126 | 11,656 |
| 2017 | 3,993 | -1,585 | -1,550 | -6.76 | 602 | 6,641 | 10,380 |
| 2018 | 3,986 | -958 | -1,011 | -4.51 | 500 | 5,121 | 8,687 |
| 2019 | 4,022 | 353 | 256 | 1.14 | 633 | 5,093 | 8,603 |
| 2020 | 3,339 | -3 | -73 | -0.33 | 635 | 4,932 | 9,350 |
| 2021 | 4,231 | 608 | 411 | 1.87 | 657 | 4,996 | 9,239 |
| 2022 | 3,922 | -937 | -950 | -4.41 | 517 | 3,811 | 7,643 |
| 2023 | 3,965 | -85 | -132 | -0.62 | 377 | 3,293 | 7,370 |
| 2024 | 3,793 | -879 | -910 | -4.48 | 461 | 1,942 | 5,753 |
| 2025 | 3,680 | 252 | -598 | -3.00 | 235 | 1,340 | 5,429 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
DENTSPLY SIRONA Inc. entwickelt, fertigt und vermarktet weltweit Dentalausrüstung mit cloudfähigen Lösungen, Dentalprodukten und Gesundheitsverbrauchsprodukten in Urologie und Enterologie.
| Employees | 14,000 |
|---|---|
| Headquarters | Charlotte, NC |
| Address | 13320 Ballantyne Corporate Place, 28277-3607 Charlotte, United States |
| Phone | 844 848 0137 |
| Website | dentsplysirona.com |
| IPO Date | 12. Aug 1987 |
| ISIN | US24906P1093 |
| Stock Split | 2:1 on 07/18/2006 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Daniel T. Scavilla | President, CEO, Interim Principal Financial Officer & Director | 1965 |
| Andrea L. Frohning | Senior VP & Chief Human Resources Officer | 1970 |
| Aldo M. Denti | Executive VP & Chief Commercial Officer | 1968 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.